| ●Editorial | Uchida E | 236 | Full text | |
| ●Dawning of the “Sunshine Act”: Towards a new phase of conflict of interest management | ||||
| Round table discussion: Dawning of the “Sunshine Act”: Towards a new phase of conflict of interest management | Uchida E，Miyaoka H， Imamura K，Iwasaki K （Organized by Kurihara C） |
237-60 | Abstract | |
| Transparency of cooperation between industry and academia and management of conflict of interest (COI)-issues involved in “Transparency Guidelines” | Kaku K | 261-5 | Abstract | |
| The role of lunch time seminar in lifelong medical education | Nango E | 267-76 | Full text | |
| Academic information and drug promotional materials | Itoh M | 277-83 | Abstract | |
| ●The 2nd International Symposium of Early Stage Clinical Trial Efficient developmental strategy that leads the world | 285-337 | Abstract | ||
| Organized by：International Symposium of Early Stage Clinical Trial The Head of the Executive Committee：Uchida E | ||||
| Opening remarks | Uchida E | 287 | ||
| How should we proceed with clinical trials in Japan given the global tide toward early clinical development? | Kumagai Y | 288-95 | ||
| Background and progress of pharmacometrics | Hayashi N | 296-301 | ||
| Application of pharmacometrics in clinical development | Miyoshi S | 302-7 | ||
| Clinical trial unit in Center for Advanced Medical Innovation Kyushu University | Ikematsu H | 308-12 | ||
| Early phase clinical trials: Pediatric viewpoint | Nakamura H | 313-9 | ||
| Clinical development of medical devices | Yamamoto H | 320-6 | ||
| Industry point of view | Shishido A | 327-31 | ||
| Plenary discussion | 332-5 | |||
| Closing remarks | Uchida E | 336 | ||
| ●The 31st Aso-Kuju Conference on Clinical Pharmacology New developments in clinical pharmacology | 339-88 | Abstract | ||
| Organizers：Ohashi K，Nomoto M，Sasaguri T，Ieiri I，Nakano S， Higuchi S，Yamada K，Hasegawa J，Sendo T | ||||
| Opening remarks | Ohashi K | 341 | ||
| Challenge of academia for drug development | Akazawa H | 342-7 | ||
| Clinical development of medical devices: Present situation | Yamamoto H | 348-54 | ||
| Proof of concept (POC) in clinical trials | Nomoto M | 355-8 | ||
| Discussion | 359-61 | |||
| Involvement and interaction of intestinal transporters for drug absorption | Tamai I | 362-71 | ||
| Current status and issues of PGx sampling in Japan | Uchida E，Tashiro S | 372-7 | ||
| Searching for disease susceptibility genes using the omics approach: A schizophrenia case | Fukumaki Y | 378-86 | ||
| Closing remarks | Nomoto M，Ohashi K | 387 | ||
| ●Symposium: From “patient-friendly medical interview” to “psychotherapy with healing power” | ||||
| From “patient-friendly medical interview” to “psychotherapy with healing
power”: Recommendation of common-sense psychiatry | Saio T | 389-94 | Full text | |
| Basics of the medical interview and Objective Structured Clinical Examination (OSCE) | Nango E | 395-400 | Full text | |
| Acquiring medical interview skills for use in psychiatric practice | Hirashima N | 401-5 | Full text | |
| Practical sleep and alcohol education for patients with mild depression | Ihara H | 407-13 | Full text | |
| Medical interview should be more utilized in the training of a psychiatric interview | Miyaoka H | 415-7 | Full text | |
| ●Original | ||||
| “Cooperative IRB” issues in Japan, United States, Europe, and Asia | Kurihara C，Kageyama S | 419-34 | Abstract | |
| ●Forum | ||||
| CDISC as the global standards ─ Does the introduction bring cost increase? | Jyono T | 435-6 | ||
| Talent development in clinical trials and research in the era of global
studies －Initiation of educational course in pharmaceutical medicine in 2013－ | Imamura K | 437-40 | Full text | |
| ●Instructions for authors [Japanese] & [English] | 441-9 | Full text | ||
| ●Editor's note | Kurihara M | 451 | Full text | |